Literature DB >> 17240119

Supportive evidence for the association between the T102C 5-HTR2A gene polymorphism and schizophrenia: a large-scale case-control and family-based study.

V E Golimbet1, O M Lavrushina, V G Kaleda, L I Abramova, T V Lezheiko.   

Abstract

Serotonin type 2A receptors (5-HTR2A) have long been implicated in schizophrenia pathology. A decreased number of these receptors were found in postmortem brain studies of schizophrenic patients as well as in experiments using neuroimaging techniques. Molecular genetic studies revealed that the T102C polymorphism of the 5-HTR2A gene is associated with schizophrenia, with the CC genotype frequency being higher in patients compared to healthy controls. However the association was not confirmed in all studies. We carried out a replication study, which aimed at searching for association between this polymorphism and schizophrenia in a large samples of patients (n=919), their psychiatrically well first-degree relatives (n=330) and screened controls (n=500). The C allele and the CT+CC genotype frequencies were significantly higher in patients than in controls (chi2=5.1; df=1; p=0.02; OR 1.2, 95% CI 1.0-1.4) and chi2=5.4; df=1; p=0.02; OR 1.4, 95% CI 1.1-1.8 respectively). In a family-based study, the transmission disequilibrium test (TDT) and the family-based association test (FBAT) did not show a preferential transmission of any allele. In conclusion, our replication study provides further evidence for association between the 5-HTR2A receptor T102C polymorphism and schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17240119     DOI: 10.1016/j.eurpsy.2006.06.002

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  7 in total

1.  Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia.

Authors:  Tiffany A Greenwood; Laura C Lazzeroni; Sarah S Murray; Kristin S Cadenhead; Monica E Calkins; Dorcas J Dobie; Michael F Green; Raquel E Gur; Ruben C Gur; Gary Hardiman; John R Kelsoe; Sherry Leonard; Gregory A Light; Keith H Nuechterlein; Ann Olincy; Allen D Radant; Nicholas J Schork; Larry J Seidman; Larry J Siever; Jeremy M Silverman; William S Stone; Neal R Swerdlow; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; Robert Freedman; David L Braff
Journal:  Am J Psychiatry       Date:  2011-04-15       Impact factor: 18.112

2.  Polymorphism of serotonin receptor genes (5-HTR2A) and Dysbindin (DTNBP1) and individual components of short-term verbal memory processes in Schizophrenia.

Authors:  M V Alfimova; M V Monakhov; L I Abramova; S A Golubev; V E Golimbet
Journal:  Neurosci Behav Physiol       Date:  2010-10

Review 3.  Kalirin signaling: implications for synaptic pathology.

Authors:  Peter Penzes; Christine Remmers
Journal:  Mol Neurobiol       Date:  2011-12-23       Impact factor: 5.590

Review 4.  From genes to psychoses and back: the role of the 5HT2alpha-receptor and prepulse inhibition in schizophrenia.

Authors:  Wolfgang Maier; Rainald Mössner; Boris B Quednow; Michael Wagner; René Hurlemann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

Review 5.  Regulating prefrontal cortex activation: an emerging role for the 5-HT₂A serotonin receptor in the modulation of emotion-based actions?

Authors:  Susana Aznar; Anders B Klein
Journal:  Mol Neurobiol       Date:  2013-05-22       Impact factor: 5.590

Review 6.  Abnormal kalirin signaling in neuropsychiatric disorders.

Authors:  Christine Remmers; Robert A Sweet; Peter Penzes
Journal:  Brain Res Bull       Date:  2013-12-12       Impact factor: 4.077

7.  Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics.

Authors:  Dalila Benmessaoud; Nora Hamdani; Claudette Boni; Nicolas Ramoz; Michel Hamon; Farid Kacha; Philip Gorwood
Journal:  BMC Psychiatry       Date:  2008-05-30       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.